ViroPharma Advances HCV-796 Into Phase Ib Testing in Hepatitis C Patients

ViroPharma has begun a Phase Ib proof-of-concept clinical study in hepatitis C-positive patients with HCV-796, a novel antiviral compound that the company is co-developing with Wyeth Pharmaceuticals, a division of Wyeth.

HCV-796 is a potent orally dosed compound that has the potential to interfere with the replication of hepatitis C virus (HCV). Preclinical studies have shown that HCV-796 is the most potent of all anti-HCV compounds developed to date between the two companies.